Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.32 (
bromelain
)
1,025
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Human peripheral blood mononuclear cells from healthy donors were treated ex vivo with the proteolytic enzyme
bromelain
and studied by flow cytometry. Bromelain-treated lymphocytes exhibited 60-90% reduced cell surface staining for CD44 and
CD62
-L molecules. While the staining for molecules CD16, CD56 and CD49d was unaffected, a moderate increase (10-40%) in expression of the beta(2)-integrins CD11a-c was seen. This selective modulation of cell adhesion molecules (CAM) was seen on T cells and NK cells, as well. The selective modulation of CAM may help explain some of the clinical effects observed after
bromelain
treatment in patients suffering from chronic inflammatory disease, HIV and cancer.
...
PMID:Selective modulation of cell adhesion molecules on lymphocytes by bromelain protease 5. 915 29
Bromelain is a general name for a family of sulfhydryl-containing, proteolytic enzymes from the pineapple plant. The aim of the present study was to investigate the influence of
bromelain
on platelet count, platelet aggregation and platelet activity in vitro. Blood samples were taken from the antecubital vein of 10 healthy male non-smokers. Platelet count decreased after incubation with 2.5 and 5 mg
bromelain
/ml from 277 +/- 17 platelets/nl before to 256 +/- 21 and 247 +/- 19 platelets/nl after the treatment. The ADP and TRAP-6 induced platelet aggregation led to a significant decrease after the incubation with 2.5 mg (ADP: 48.6 +/- 25.7%; TRAP-6: 49.6 +/- 28.9%) or 5 mg (ADP: 5.0 +/- 4.6%; TRAP-6: 9.0 +/- 4.9%)
bromelain
/ml in comparison to control (ADP: 81.4 +/- 5.0%; TRAP-6: 77.4 +/- 10.4%). The percentage of unstimulated
CD62P
positive platelets which were investigated by flow cytometry was minimally higher after incubation with 5 mg
bromelain
/ml (0.57 +/- 0.48% PC) in comparison to control (0.22 +/- 0.11% PC), but after TRAP-6 stimulation the incubation with 5 mg
bromelain
/ml led to a remarkable decrease in comparison to the untreated control (50.4 +/- 20.2 to 0.9 +/- 0.8% PC). The changes of
CD62P
(TRAP-stimulated) and the results of platelet aggregation after incubation with
bromelain
in vitro may demonstrate the potential of
bromelain
as a substance for platelet inhibition.
...
PMID:The influence of bromelain on platelet count and platelet activity in vitro. 1630 85